It may take more than an enhanced dividend and improved share-swap ratio to win shareholder approval for the $12.4b merger, a deal tied to the reorganisation of Li's businesses.
Scorching competition in the online-to-offline sector motivated the former rivals to agree to the merger, creating a Chinese O2O heavyweight capable of taking on Baidu's Nuomi.
The private equity firm has bought prime San Francisco real estate to incubate Asian disruptive tech companies.
A free-trade deal between Beijing and Canberra is making it easier for Chinese companies and individuals to acquire assets in Australia.
The Chinese baby formula maker's deal for Australia's Swisse Wellness shows SOEs have rivals for overseas M&A targets. But some wonder if Biostime is fighting above its weight.
The US private equity firm's third Japan buyout fund closed after a protracted fundraising exercise that saw it enlist new and existing investors.
Hao Capital injects $12.5m; Olympus Capital Asia invests $40m; BCG forecasts China’s digital healthcare market to grow to $110 billion by 2020.
The US private equity firm's purchase of a stake in the pathology laboratories chain signals an end to a boardroom battle triggered by Warburg Pincus' exit earlier this year.
The Japanese insurer is catching up with its peers who are already in the Lloyd's market.
After losing out on the sale of Singapore’s APL Logistics earlier this year, Korea’s largest logistics company has won control of China’s Rokin.
After winning a highly competitive auction, MBK must roll up its sleeves and work hard to stop falling like-for-like sales at Tesco’s Korean retail unit.
Irish aircraft lessor Avolon gets snapped up at an attractive valuation underscoring China's growing appetite for M&A within the global jet leasing sector.
The north Asia-focused private equity firm is stepping up in terms of deal size with the purchase of Tesco’s Korean discount retailer.
The UK bank woos away former JP Morgan banker Duncan Hogg to head mergers and acquisitions, in line with the build-out of its investment banking division Down Under.
Baring Private Equity Asia closes purchase of 40% stake in Weetabix and plans expansion in China. Loan financing largely taken up by Chinese banks.